JPH06501152A - 動物およびヒトにおける感染の治療および予防用の新規な抗体 - Google Patents

動物およびヒトにおける感染の治療および予防用の新規な抗体

Info

Publication number
JPH06501152A
JPH06501152A JP3514980A JP51498091A JPH06501152A JP H06501152 A JPH06501152 A JP H06501152A JP 3514980 A JP3514980 A JP 3514980A JP 51498091 A JP51498091 A JP 51498091A JP H06501152 A JPH06501152 A JP H06501152A
Authority
JP
Japan
Prior art keywords
antibody
antibodies
modified
human
rsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3514980A
Other languages
English (en)
Japanese (ja)
Inventor
ハリス，ウィリアム・ジェイ
テンペスト，フィリップ・アール
テイラー，ジェラルディン
Original Assignee
スコットジェン・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スコットジェン・リミテッド filed Critical スコットジェン・リミテッド
Publication of JPH06501152A publication Critical patent/JPH06501152A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP3514980A 1990-09-11 1991-09-11 動物およびヒトにおける感染の治療および予防用の新規な抗体 Pending JPH06501152A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909019812A GB9019812D0 (en) 1990-09-11 1990-09-11 Novel antibodies for treatment and prevention of infection in animals and man
GB9019812.8 1990-09-11

Publications (1)

Publication Number Publication Date
JPH06501152A true JPH06501152A (ja) 1994-02-10

Family

ID=10682003

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3514980A Pending JPH06501152A (ja) 1990-09-11 1991-09-11 動物およびヒトにおける感染の治療および予防用の新規な抗体

Country Status (12)

Country Link
EP (1) EP0548190A1 (pt)
JP (1) JPH06501152A (pt)
KR (1) KR930702519A (pt)
AU (1) AU654827B2 (pt)
CA (1) CA2091335A1 (pt)
GB (1) GB9019812D0 (pt)
IE (1) IE913177A1 (pt)
MX (1) MX9101046A (pt)
NZ (1) NZ239728A (pt)
PT (1) PT98944B (pt)
WO (1) WO1992004381A1 (pt)
ZA (1) ZA917170B (pt)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40070E1 (en) 1994-02-22 2008-02-19 Smithkline Beecham Corporation Antibody purification
JP2011528720A (ja) * 2008-07-21 2011-11-24 イミューノメディクス、インコーポレイテッド 改善された治療上の特徴のための抗体の構造変異体

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DK0539522T3 (da) * 1990-07-19 1999-08-30 Us Commerce Forbedret immunterapeutisk fremgangsmåde til hindring eller behandling af viral sygdom i luftvejene
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5646253A (en) * 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
DK0671927T3 (da) * 1992-09-16 2003-04-22 Us Gov Health & Human Serv Neutraliserende humane monoklonale antistoffer mod respiratorisk syncytialvirus
US6685942B1 (en) 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
WO1995004081A1 (en) * 1993-07-30 1995-02-09 Oravax, Inc. MONOCLONAL IgA ANTIBODY AGAINST RESPIRATORY SYNCYTIAL VIRUS
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
WO1995031546A1 (en) * 1994-04-28 1995-11-23 Scotgen Biopharmaceuticals, Inc. Recombinant human anti-varicella zoster virus antibodies
ATE194291T1 (de) 1995-09-18 2000-07-15 Intracel Corp Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
JP4503706B2 (ja) 1996-06-07 2010-07-14 ポニアード ファーマシューティカルズ，インコーポレイティド グリコシル化が改質されたヒト化抗体
DK0970206T3 (da) 1997-01-27 2008-10-13 Ludwig Inst Cancer Res Lage-1-tumorassocierede nukleinsyrer
EP2305235A1 (en) 1997-04-02 2011-04-06 The Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
HK1041009B (en) 1998-12-30 2009-05-08 Beth Israel Deaconess Medical Center, Inc. Characterization of the soc/crac calcium channel protein family
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
JP2003527826A (ja) 1999-06-30 2003-09-24 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 癌関連抗原およびその使用
PT1207905E (pt) 1999-09-03 2010-12-07 Brigham & Womens Hospital Métodos e composições para o tratamento de doença inflamatória utilizando agentes moduladores da caderina-11
KR20020047249A (ko) 1999-10-19 2002-06-21 에드워드 에이. 맥더모트, 주니어 Ｍａｇｅ-ａ12 항원성 펩티드 및 그의 용도
HK1049944A1 (zh) * 1999-12-23 2003-06-06 Icn Pharmaceuticals, Inc. L-核苷、l-核苷酸及其类似物的组合物和治疗方法
WO2001097843A2 (en) 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CN101444621B (zh) 2003-02-11 2013-11-20 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
DK2384753T3 (en) 2003-08-29 2016-04-11 Brigham & Womens Hospital Hydantoin derivatives as inhibitors of cell necrosis
DE10341812A1 (de) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1795596A1 (en) 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
DE102005059242A1 (de) 2005-12-12 2007-06-14 Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten Molekulare Marker für eine Tumordiagnose und -therapie
CN101421411B (zh) 2006-04-13 2015-06-03 中外制药株式会社 牛磺酸转运蛋白基因
EP1911851A1 (en) 2006-10-12 2008-04-16 Ganymed Pharmaceuticals AG Compositions and methods for therapy and diagnosis of cancer and cancer metastasis
EP2118141B1 (en) 2007-02-23 2014-07-30 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that neutralize anthrax toxins
WO2008114673A1 (ja) 2007-03-15 2008-09-25 Chugai Seiyaku Kabushiki Kaisha ポリペプチドの製造方法
ES2591284T3 (es) 2007-08-07 2016-11-25 Chugai Seiyaku Kabushiki Kaisha Método para la producción de proteínas heterogéneas
WO2009051109A1 (ja) 2007-10-15 2009-04-23 Chugai Seiyaku Kabushiki Kaisha 異種タンパク質を高生産する細胞の作製方法
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
AU2008314973C1 (en) * 2007-10-24 2014-05-08 Chugai Seiyaku Kabushiki Kaisha A cell for use in production of heteroproteins and production method using the same
EP2108701A1 (en) 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
ES2963717T3 (es) 2009-02-20 2024-04-01 Astellas Pharma Inc Métodos y composiciones para el diagnóstico y tratamiento del cáncer
EP2221375A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
US8741601B2 (en) 2009-04-22 2014-06-03 Chugai Seiyaku Kabushiki Kaisha Method for producing a cell capable of high-yield production of heteroproteins
EP2249159A1 (en) 2009-04-29 2010-11-10 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
RU2675997C2 (ru) 2009-11-11 2018-12-25 Ганимед Фармасьютикалз Аг Антитела, специфичные к клаудину 6 (cldn6)
EA201291065A1 (ru) 2010-04-16 2013-03-29 Байоджен Айдек Ма Инк. Антитела против vla-4
WO2011133894A2 (en) 2010-04-23 2011-10-27 Purdue Research Foundation Protein drug formulations and packages
AU2011248184B2 (en) 2010-05-04 2015-12-17 Board Of Regents, The University Of Texas System Detection and treatment of fibrosis
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
RS58087B1 (sr) 2011-05-13 2019-02-28 Ganymed Pharmaceuticals Gmbh Antitela za lečenje kancera koji eksprimira klaudin 6
US20140322723A1 (en) 2011-11-22 2014-10-30 President and Dellows of Harvard College Diabetes diagnosis through the detection of glycated proteins in urine
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CN106163560A (zh) 2014-01-24 2016-11-23 亨利·M·杰克逊军事医学促进基金会 针对亨德拉和尼帕病毒的f糖蛋白的抗体
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
US10899829B2 (en) 2016-02-23 2021-01-26 Indiana University Research And Technology Corporation Emapii neutralizing antibody limits influenza A virus (IAV)-induced lung injury
US11534496B2 (en) 2016-06-07 2022-12-27 The Brigham And Women's Hospital, Inc. Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions
EP3625254B1 (en) 2017-07-31 2023-12-13 F. Hoffmann-La Roche AG Three-dimensional structure-based humanization method
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40070E1 (en) 1994-02-22 2008-02-19 Smithkline Beecham Corporation Antibody purification
USRE41555E1 (en) 1994-02-22 2010-08-24 Glaxosmithkline Llc Antibody purification
USRE41595E1 (en) 1994-02-22 2010-08-31 Glaxosmithkline Llc Antibody purification
JP2011528720A (ja) * 2008-07-21 2011-11-24 イミューノメディクス、インコーポレイテッド 改善された治療上の特徴のための抗体の構造変異体

Also Published As

Publication number Publication date
IE913177A1 (en) 1992-03-11
GB9019812D0 (en) 1990-10-24
WO1992004381A1 (en) 1992-03-19
NZ239728A (en) 1995-07-26
KR930702519A (ko) 1993-09-09
AU654827B2 (en) 1994-11-24
MX9101046A (es) 1992-05-04
ZA917170B (en) 1992-07-29
EP0548190A1 (en) 1993-06-30
PT98944A (pt) 1992-08-31
PT98944B (pt) 1999-02-26
CA2091335A1 (en) 1992-03-12
AU8505891A (en) 1992-03-30

Similar Documents

Publication Publication Date Title
AU654827B2 (en) Novel antibodies for treatment and prevention of infection in animals and man
KR101671452B1 (ko) 항ｒｓｖ ｇ 단백질 항체
AU679440B2 (en) Antibodies for treatment and prevention of respiratory syncytial virus infection
Tempest et al. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo
US5955364A (en) Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
TWI785583B (zh) 一種抗新型冠狀病毒的單克隆抗體及其應用
FI108991B (fi) Menetelmä ihmisen monoklonaalisen vasta-aineen tuottamiseksi
CN113874394B (zh) 抗体
WO1993020210A9 (en) Antibodies for treatment and prevention of respiratory syncytial virus infection
WO2021174595A1 (zh) 一种抗新型冠状病毒的单克隆抗体及其应用
JPH10504195A (ja) 呼吸シンシチアルウイルスを防ぐヒト−マウスキメラ抗体
JP7533897B2 (ja) 融合タンパク質およびその使用
JP2007533330A (ja) クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用
CZ292295B6 (cs) Rekombinantní protilátková molekula, DNA sekvence, terapeutická nebo diagnostická kompozice a použití protilátkové molekuly
US5607847A (en) Recombinant human anti-human immunodeficiency virus antibody
WO2011068143A1 (ja) Ｈ５亜型インフルエンザウイルスに対する抗体およびその利用
KR102937383B1 (ko) 개파보바이러스 특이적 항체 cpv-b3 및 이를 포함하는 개파보바이러스 감염증 치료용 약제학적 조성물
CN114773461B (zh) 乙型脑炎病毒抗体1d11及其应用
WO2022122788A1 (en) Multispecific antibodies against severe acute respiratory syndrome coronavirus 2
KR102934959B1 (ko) 개파보바이러스 특이적 항체 cpv-f12 및 이를 포함하는 개파보바이러스 감염증 치료용 약제학적 조성물
NZ250415A (en) Monoclonal antibody directed against rsv epitope 417-438, its use and production
CN103374072B (zh) 一种抗Mac‑2BP人源化抗体的制备
WO2022199527A1 (zh) 靶向肺炎链球菌溶血素的抗原结合蛋白及其用途
CN121824774A (zh) 一种治疗李斯特菌病的双特异性抗体及其药物组合物
HK40064293A (en) Novel anti-hepatitis b virus antibody and uses thereof